205 related articles for article (PubMed ID: 35025619)
21. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
[TBL] [Abstract][Full Text] [Related]
23. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ; Kim HT; Zhao L; Murdock HM; Hambley B; Ogata A; Madero-Marroquin R; Wang S; Green L; Fleharty M; Dougan T; Cheng CA; Blumenstiel B; Cibulskis C; Tsuji J; Duran M; Gocke CD; Antin JH; Nikiforow S; DeZern AE; Chen YB; Ho VT; Jones RJ; Lennon NJ; Walt DR; Ritz J; Soiffer RJ; Gondek LP; Lindsley RC
J Clin Oncol; 2022 Jan; 40(2):189-201. PubMed ID: 34793200
[TBL] [Abstract][Full Text] [Related]
24. A Rapid and Safe Infusion Protocol for
Ebbers SC; Barentsz MW; de Keizer B; Krijger GC; Lam MGEH; Braat AJAT
J Nucl Med; 2021 Jun; 62(6):816-822. PubMed ID: 33246981
[TBL] [Abstract][Full Text] [Related]
25. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
26. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN; Miller CA; Jotte MRM; Bagegni N; Baty JD; Schmidt AP; Cashen AF; Duncavage EJ; Helton NM; Fiala M; Fulton RS; Heath SE; Janke M; Luber K; Westervelt P; Vij R; DiPersio JF; Welch JS; Graubert TA; Walter MJ; Ley TJ; Link DC
Nat Commun; 2018 Jan; 9(1):455. PubMed ID: 29386642
[TBL] [Abstract][Full Text] [Related]
27. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.
Zink F; Stacey SN; Norddahl GL; Frigge ML; Magnusson OT; Jonsdottir I; Thorgeirsson TE; Sigurdsson A; Gudjonsson SA; Gudmundsson J; Jonasson JG; Tryggvadottir L; Jonsson T; Helgason A; Gylfason A; Sulem P; Rafnar T; Thorsteinsdottir U; Gudbjartsson DF; Masson G; Kong A; Stefansson K
Blood; 2017 Aug; 130(6):742-752. PubMed ID: 28483762
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
29. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
Sonbol MB; Halfdanarson TR; Hilal T
JAMA Oncol; 2020 Jul; 6(7):1086-1092. PubMed ID: 32297906
[TBL] [Abstract][Full Text] [Related]
31. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
32. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
33. Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
Kwan TT; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Aghajanian C; Lorusso D; Colombo N; Dean A; Weberpals J; Severson E; Vo LT; Goble S; Maloney L; Harding T; Kaufmann SH; Ledermann JA; Coleman RL; McNeish IA; Lin KK; Swisher EM
JAMA Oncol; 2021 Dec; 7(12):1772-1781. PubMed ID: 34647981
[TBL] [Abstract][Full Text] [Related]
34. PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
Miller PG; Sperling AS; Mayerhofer C; McConkey ME; Ellegast JM; Da Silva C; Cohen DN; Wang C; Sharda A; Yan N; Saha S; Schluter C; Schechter I; Słabicki M; Sandoval B; Kahn J; Boettcher S; Gibson CJ; Scadden DT; Stegmaier K; Bhatt S; Lindsley RC; Ebert BL
Blood; 2023 Dec; 142(24):2079-2091. PubMed ID: 37595362
[TBL] [Abstract][Full Text] [Related]
35. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
36. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort.
Heckert JM; Kipnis ST; Kumar S; Botterbusch S; Alderson A; Bennett B; Creamer C; Eads JR; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Katona BW
Oncologist; 2020 Jul; 25(7):572-578. PubMed ID: 32141667
[TBL] [Abstract][Full Text] [Related]
37. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
38. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
39. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
[TBL] [Abstract][Full Text] [Related]
40. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
